XML 66 R112.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 29, 2019 | Sep. 29, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 30, 2018 | Sep. 30, 2018 | Jul. 01, 2018 | Apr. 01, 2018 | Dec. 29, 2019 | Dec. 30, 2018 | Dec. 31, 2017
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers | $ 20,747 | $ 20,729 | $ 20,562 | $ 20,021 | $ 20,394 | $ 20,348 | $ 20,830 | $ 20,009 | $ 82,059 | $ 81,581 | $ 76,450
Earnings before provision for taxes on income | 4,218 | 1,647 | 7,041 | 4,422 | 3,122 | 4,423 | 4,973 | 5,481 | 17,328 | 17,999 | 17,673
Identifiable Assets | 157,728 |  |  |  | 152,954 |  |  |  | 157,728 | 152,954 |
Additions to Property, Plant & Equipment |  |  |  |  |  |  |  |  | 3,498 | 3,670 | 3,279
Depreciation and Amortization |  |  |  |  |  |  |  |  | 7,009 | 6,929 | 5,642
United States |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 42,097 | 41,884 | 39,863
Non-US |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 39,962 | 39,697 | 36,587
Consumer |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers | 3,567 | 3,469 | 3,544 | 3,318 | 3,536 | 3,415 | 3,504 | 3,398 | 13,898 | 13,853 | 13,602
Consumer | United States |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 5,839 | 5,761 | 5,565
Consumer | Non-US |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 8,059 | 8,092 | 8,037
Pharmaceutical |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers | 10,548 | $ 10,877 | $ 10,529 | $ 10,244 | 10,190 | $ 10,346 | $ 10,354 | $ 9,844 | 42,198 | 40,734 | 36,256
Pharmaceutical | United States |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 23,874 | 23,286 | 21,474
Pharmaceutical | Non-US |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 18,324 | 17,448 | 14,782
Medical Devices |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 25,963 | 26,994 | 26,592
Medical Devices | United States |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 12,384 | 12,837 | 12,824
Medical Devices | Non-US |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 13,579 | 14,157 | 13,768
Operating Segments |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Identifiable Assets | 132,372 |  |  |  | 128,767 |  |  |  | 132,372 | 128,767 |
Additions to Property, Plant & Equipment |  |  |  |  |  |  |  |  | 3,190 | 3,293 | 2,987
Depreciation and Amortization |  |  |  |  |  |  |  |  | 6,689 | 6,593 | 5,306
Corporate, Non-Segment |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Less: Expense not allocated to segments |  |  |  |  |  |  |  |  | 835 | 1,286 | 1,326
Corporate, Non-Segment | General Corporate |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Identifiable Assets | 25,356 |  |  |  | 24,187 |  |  |  | 25,356 | 24,187 |
Additions to Property, Plant & Equipment |  |  |  |  |  |  |  |  | 308 | 377 | 292
Depreciation and Amortization |  |  |  |  |  |  |  |  | 320 | 336 | 336
Operating Segments |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 82,059 | 81,581 | 76,450
Earnings before provision for taxes on income |  |  |  |  |  |  |  |  | 18,163 | 19,285 | 18,999
Operating Segments | United States |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 42,097 | 41,884 | 39,863
Operating Segments | Consumer |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Earnings before provision for taxes on income |  |  |  |  |  |  |  |  | 2,061 | 2,320 | 2,524
Identifiable Assets | 26,618 |  |  |  | 25,877 |  |  |  | 26,618 | 25,877 |
Additions to Property, Plant & Equipment |  |  |  |  |  |  |  |  | 328 | 438 | 485
Depreciation and Amortization |  |  |  |  |  |  |  |  | 765 | 688 | 674
Operating Segments | Pharmaceutical |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Earnings before provision for taxes on income |  |  |  |  |  |  |  |  | 8,816 | 12,568 | 11,083
Identifiable Assets | 56,292 |  |  |  | 56,636 |  |  |  | 56,292 | 56,636 |
Additions to Property, Plant & Equipment |  |  |  |  |  |  |  |  | 950 | 1,012 | 936
Depreciation and Amortization |  |  |  |  |  |  |  |  | 3,910 | 3,802 | 2,416
Operating Segments | Medical Devices |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Earnings before provision for taxes on income |  |  |  |  |  |  |  |  | 7,286 | 4,397 | 5,392
Identifiable Assets | $ 49,462 |  |  |  | $ 46,254 |  |  |  | 49,462 | 46,254 |
Additions to Property, Plant & Equipment |  |  |  |  |  |  |  |  | 1,912 | 1,843 | 1,566
Depreciation and Amortization |  |  |  |  |  |  |  |  | 2,014 | 2,103 | 2,216
Immunology | Pharmaceutical |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 13,950 | 13,120 | 12,244
Immunology | Pharmaceutical | United States |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | 9,641 | 9,073 | 8,871
Immunology | Pharmaceutical | Non-US |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |
Sales to Customers |  |  |  |  |  |  |  |  | $ 4,309 | $ 4,047 | $ 3,373

X
- Definition Expense not allocated to segments. + References No definition available. + Details
Name: | jnj_ExpenseNotAllocatedToSegments
Namespace Prefix: | jnj_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 + Details
Name: | us-gaap_Assets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 + Details
Name: | us-gaap_DepreciationDepletionAndAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)(1)(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + References No definition available. + Details
Name: | us-gaap_PropertyPlantAndEquipmentAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |